Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohort.
Fiche publication
Date publication
août 2023
Journal
European journal of gastroenterology & hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Nguyen-Khac E, Nahon P, Ganry O, Ben Khadhra H, Merle P, Amaddeo G, Ganne-Carrie N, Silvain C, Peron JM, Mathurin P, Anty R, Uguen T, Decaens T, Riachi G, Bouattour M, Baron A, Bronowicki JP, Pageaux GP, Rosmorduc O, Ducournau G, Gilberg M, Tanang A, Dupin J, Gilbert-Marceau A, Blanc JF,
Lien Pubmed
Résumé
Hepatocellular carcinoma epidemiological data are limited in France. The Epidemio Liver Immunotherapy Tecentriq outcome research (ELITor) retrospective study, based on real-world data from the Carcinome HépatocellulaIrE en France (CHIEF) French cohort of hepatocellular carcinoma patients, aimed to get insight into the treatment patterns, the sociodemographic, clinical, biological, and etiological characteristics, and the quality of life of patients with unresectable hepatocellular carcinoma.
Référence
Eur J Gastroenterol Hepatol. 2023 08 14;: